Researchers Develop AI Framework for Personalized Cancer Treatment Using Active Inference
Researchers have developed a belief-space planning framework using active inference to guide personalized cancer treatment decisions under real-world clinical constraints. The approach models cancer treatment as a sequential decision-making problem that accounts for partial information, patient variability, and limits on medical measurements. The work aims to improve on standard reinforcement learning methods by explicitly handling how treatments alter patient biology over time.
A new preprint posted to arXiv proposes modeling cancer treatment as a belief-space planning problem using active inference, a framework that balances goal-directed control with information gathering when measurement budgets are limited. Unlike conventional reinforcement learning approaches, the method accounts for the fact that cancer treatments permanently modify a patient's underlying biological dynamics rather than simply steering a fixed system toward a desired state. The researchers derive an expected free-energy objective that simultaneously drives treatment efficacy and guides decisions about when and what to measure. The framework was implemented and tested using real clinical data from the AACR Project GENIE Biopharma Collaborative dataset, a large multi-institutional cancer genomics resource. Results reportedly demonstrate simultaneous patient categorization and high treatment efficacy while respecting realistic measurement and treatment constraints. The work is presented as an 11-page paper including appendix and has not yet undergone formal peer review.
What's missing
As a preprint, the paper has not been peer-reviewed. Key open questions include: how the framework performs compared to established clinical treatment protocols or other RL baselines on standardized benchmarks; whether the patient categorization produced is clinically interpretable or actionable; how sensitive results are to the choice of prior beliefs; and whether the approach has been validated prospectively or only retrospectively on the GENIE dataset. The abstract does not specify which cancer types were studied or the scale of the patient cohort used.
What different sources said
- arXiv cs.AICenter
Belief-Space Control for Personalized Cancer Treatment via Active Inference
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.